Sage's oral postpartum depression drug ticks efficacy, safety boxes in key trial, easing fears of fainting risk
Pivotal data on Sage Therapeutics’ $SAGE keenly-watched oral postpartum depression (PPD) drug showed that there was no loss of consciousness associated with the experimental treatment, unlike the drug developer’s brexanolone — which must be administered via an infusion and is currently under FDA review. Late-stage data showed the potential blockbuster drug, SAGE-217, met the primary endpoint, although a serious adverse event was observed in both the drug and placebo arm, the company said on Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.